Related Experiment Video
Updated: Dec 17, 2025
Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Recent successes in therapeutics for Ebola virus disease: no time for complacency
Patrick L Iversen1, Christopher D Kane1, Xiankun Zeng1
1United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA.
Abstract:
The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics in the treatment of acute Ebola virus disease; however, substantial gaps remain in improving the outcomes of acute Ebola virus disease and for the survivors. Ongoing efforts are needed to develop more effective strategies, particularly for individuals with severe disease, for prevention and treatment of viral persistence in immune-privileged sites, for optimisation of post-exposure prophylaxis, and to increase therapeutic breadth. As antibody-based approaches are identified and advanced, promising small-molecule antivirals currently in clinical stage development should continue to be evaluated for filovirus diseases, with consideration of their added value in combination approaches with bundled supportive care, their penetration in tissues of interest, the absence of interaction with glycoprotein-based vaccines, and filoviral breadth.
Insights
The PALM trial showed monoclonal antibodies improve survival for acute Ebola virus disease. Further research is crucial for severe cases, viral persistence, and broader treatment options.
Area of Science:
- Infectious Diseases
- Virology
- Clinical Trials
Background:
- Ebola virus disease (EVD) poses a significant global health threat.
- Monoclonal antibody therapeutics have emerged as a treatment modality for EVD.
- Gaps persist in optimizing EVD treatment and survivor care.
Purpose of the Study:
- To evaluate the efficacy of monoclonal antibody-based therapeutics in acute EVD.
- To identify areas for improvement in EVD management and post-treatment care.
- To guide future research and development of novel antiviral strategies.
Main Methods:
- The study involved the PALM trial conducted in the Democratic Republic of the Congo.
- Analysis focused on survival benefits associated with two monoclonal antibody therapeutics.
- Consideration of ongoing research needs for severe EVD and viral persistence.
Main Results:
- A statistically significant survival benefit was observed with the tested monoclonal antibody therapeutics.
- Substantial challenges remain in enhancing outcomes for acute EVD and for survivors.
- Need for advanced strategies targeting severe disease and viral persistence.
Conclusions:
- Monoclonal antibodies offer a survival benefit in acute EVD treatment.
- Continued development of effective strategies is essential for severe EVD and long-term survivor health.
- Further evaluation of small-molecule antivirals and combination therapies is warranted for filovirus diseases.
Related Concept Videos
00:42Cross-reactivity
01:29Microorganisms in Medicine and Therapeutics